VK-2019 for relapsed/refractory EBV-positive DLBCL
Part of Infections clinical trials.
This trial tests a new drug called VK-2019 for people whose EBV-positive diffuse large B-cell lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this drug can shrink tumors and help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of lymphoma called EBV-positive diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior treatments.
- You have tried all standard treatments that could help, and they are no longer working.
- You are at least 18 years old.
- You are able to walk and take care of yourself (ECOG performance status 0 to 2).
- Your blood counts and organ function (kidney, liver) are within acceptable ranges.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs (PD-1 inhibitor, tenofovir, chidamide, and lenalidomide) to treat diseases caused by the Epstein-Barr virus (EBV). The goal is to see if this combination can reduce the virus and improve symptoms.
This trial tests a new study treatment called KSD-101 for blood cancers linked to the Epstein-Barr virus (EBV) that have come back or not responded to other treatments. The goal is to see if it is safe and effective for people with these types of cancer.
This study tests a new injection called KSV01 for people with a type of lymphoma (DLBCL) that has returned or not responded to previous treatments. The goal is to see if it can help shrink tumors or stop the disease from getting worse.
This trial tests an investigational mRNA vaccine (WGc-043) that aims to help your immune system fight EBV-positive lymphoma cells. If you have tried standard treatments and your lymphoma is still active, this vaccine might offer a new option.
This study tests a combination of four drugs (an immunotherapy called a PD-1 inhibitor, an antiviral drug called tenofovir, and two other targeted therapies) for people whose EBV-related lymphoma has come back or not improved after treatment. The goal is to see if this combination can control the disease and help patients live longer.
This study tests a new drug called CN201 (also known as MK-1045) for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The goal is to see if the drug can help shrink or control the cancer.
Hear when a new Diffuse Large B Cell Lymphoma Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.